Akebia draws $60M from Symbiotic Capital to retire BlackRock debt
What's the deal? Akebia Therapeutics has entered a senior secured term loan facility with Symbiotic CapitalDealroom has a profile for this one. Try Dealroom → worth up to $140 million. The initial $60 million tranche was fully funded at closing on November 12, 2026, and an incremental $80 million is available at Symbiotic's discretion.
Where it went: Akebia used the initial tranche to fully repay its $55 million loan facility with BlackRock. The new facility carries a 60-month maturity, a 60-month interest-only period, and a variable monthly rate of the greater of WSJ Prime plus 4.5% or 11.5%.
Why now? The move is a refinancing play rather than fresh growth capital. In its latest quarter, Akebia held $159.3 million in cash but said its two-year runway depended on refinancing the existing senior secured loan, with principal payments due to begin in January 2027.
What's the endgame? The Waltham, Massachusetts biopharmaceutical company, founded in 2007, focuses on kidney disease. Chief financial and business officer Erik Ostrowski said the deal "enhances our operational flexibility" and gives access to "additional non-dilutive capital," while reaffirming cash-runway guidance of at least two years.
The backdrop: Akebia's operating picture is mixed. Its Vafseo patient base grew about 140% year over year, but total revenue fell to $36.9 million from $58.8 million as Auryxia faced generic competition and pricing pressure.
What could go wrong? The deal's impact hinges on execution. Whether the facility meaningfully eases refinancing risk depends on the incremental tranche being funded, plus pricing and covenants — and the discretionary $80 million is not guaranteed.
The signal: For a small-cap biopharma facing looming debt maturities and softening legacy revenue, non-dilutive credit from a specialist healthcare lender offers a route to buy time without tapping equity. Symbiotic's senior managing director Chris York cited Akebia's "portfolio of revenue-generating products and a pipeline focused on kidney disease" as the draw.
Read more: Business Insider
Image credit: "14-1000-056" by NavyMedicine, public domain (Public Domain Mark 1.0)